BiondVax’s Flu Vaccine Trial Recruitment Complete

 April 4, 2016 | Israel’s BiondVax Pharmaceuticals announced today that recruitment of all 224 participants in a Phase 2b clinical trial of M-001, its universal flu vaccine candidate, is complete. The trial, conducted in collaboration with the EU-sponsored UNISEC consortium, is designed to evaluate the safety and immunogenicity of M-001 when used ahead of an avian influenza vaccine. According to the company, this milestone brings their multi-strain and multi-season vaccine against seasonal and pandemic flu one step closer to market. Results from this trial are expected late 2016 or early 2017. BiondVax was founded in 2003 and is headquartered in Nes Ziona.